Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivaroxaban Granules vs Tablets in Healthy Men
NCT04720092Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in thromboembolic disorders (2 arms), sponsored by Bayer. Primary endpoints: Area under the concentration versus time curve from zero to infinity, Area under the concentration versus time curve from zero to last quantifiable data point and 1 more. Started Jul 2017; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolic disorders
Beyond the preview
Go deeper on NCT04720092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720092.